PET in the diagnostic evaluation of adrenal tumors

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 51, Issue 3, 2007, Pages 272-283

  Gross, M D ^a,b   Avram, A ^a   Fig, L M ^a,b   Fanti, S ^c   Al Nahhas, A ^d   Rubello, D ^e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Adrenal cortex neoplasm; Adrenal gland diseases; Radiopharmaceuticals; Tomography, emission computed

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 131; 5 HYDROXYTRYPTOPHAN C 11; ACETIC ACID C 11; ADRENALIN C 11; CARBON 11; CATECHOLAMINE; CATECHOLAMINE DERIVATIVE; CHOLESTERYL P FLUOROBENZOATE F 18; CHOLINE C 11; CONTRAST MEDIUM; DOPAMINE F 18; ETOMIDATE C 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUORODOPA F 18; FLUORODOPAMINE F 18; HYDROXYEPHEDRINE C 11; METOMIDATE C 11; NONIONIC CONTRAST MEDIUM; OCTREOTIDE; OCTREOTIDE[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE] GA 68; OCTREOTIDE[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TRIENTINE] CU 64; PENTETREOTIDE IN 110M; PHENYLEPHRINE C 11; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ADRENAL CORTEX; ADRENAL CORTEX CARCINOMA; ADRENAL FUNCTION; ADRENAL INCIDENTALOMA; ADRENAL MEDULLA; ADRENAL METASTASIS; ADRENAL SCINTISCANNING; ADRENAL TUMOR; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG METABOLISM; DRUG UPTAKE; HUMAN; HYPERCORTISOLISM; HYPERTENSIVE CRISIS; IMAGE QUALITY; INTERMETHOD COMPARISON; NEURAL CREST; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIMARY HYPERALDOSTERONISM; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; HUMANS; IMAGE ENHANCEMENT; MOLECULAR PROBE TECHNIQUES; POSITRON-EMISSION TOMOGRAPHY;

EID: 34547579675     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Gross MD, Shapiro B, Bui C, Shulkin B, Sisson J. Adrenal scintigraphy and metaiodobenzylguanidine therapy of neuroendocrine tumors. In: Sandler MP, Coleman RE, Patton JA, Wackers FJT, Gottschalk A, editors. Diagnostic nuclear medicine, 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2003.p.715-34.
2. Gross MD, Bui C, Shapiro B. Adrenocortical scintigraphy. In: Ell PJ, Gambhir SS, editors. Nuclear medicine in clinical diagnosis and treatment, 3rd ed. Edinburgh: Churchill and Livingstone.p.45-52.
3. Avram A, Fig LM, Gross MD. Nuclear imaging of the adrenal gland. Semin Nucl Med 2006;36:212-27.
4. Eriksson B, Bergström M, Sundin A, Juhlin C, Örlefors H, Öberg K et al. The role of PET in the localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci 2002; 970:159-69.
5. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med 2004;48:150-63.
6. Kainberger F, Kurtaran A, Kienast O, Dobrozemsky G, Czerny C, Kletter K. [Hybrid imaging for endocrine diseases: new perspectives]. Wien Klin Wochenschr 2003;115 Suppl 2:87-90.
7. 18F]Fluorobenzoate. Nucl Med Biol 1999;26:131-8.
8. Bergstrom M, Bonasera TA, Lu L, Bergstrom E, Backlin C, Juhlin C et al. In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med 1998;39:982-9.
9. 11C-metomidate. J Nucl Med 2000;41:275-82.
10. Gross MD, Valk TW, Thrall JH, Beierwaltes WH. The role of pharmacologic manipulation in adrenal cortical scintigraphy. Semin Nucl Med 1981;11:128-48.
11. Gross MD, Shapiro, B. Scintigraphic studies in adrenal hypertension. Semin Nucl Med 1990;19:122-43.
12. Beierwaltes WH, Wieland DM, Swanson DP. Radiolabeled enzyme inhibitors for imaging. In: Columbetti LG, editor. Principles of radiopharmacology. Boca Raton: CRC Press; 1979.p.41.
13. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004;25:568-80.
14. Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, Langsjo J et al. Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. J Nucl Med 2004;45:972-9.
15. 11C-metomidate. Eur J Nucl Med Mol Imaging 2004;31: 1224-30.
16. Gross MD, Rubello D, Shapiro B. Is there a future for adrenal scintigraphy? Nucl Med Commun 2002;23:197-202.
17. Ilias I, Pacak K. Anatomical and functional imaging of metastatic pheochromocytoma. Ann N Y Acad Sci 2004;1018:495-504.
18. Eriksson B, Bergström M, Sundin A, Juhlin C, Örlefors H, Öberg K et al. The role of PET in the localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci 2002; 970:159-69.
19. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001;42:1795-19.
20. 18F-FDG PFT/CT in the evaluation of adrenal masses. J Nucl Med 2006;47:32-7.
21. 68GA]DOTA- D-Phel-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 2001;42:1053-6.
22. 123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun 2006;27:31-6.
23. 111In-octreoticle uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685-93.
24. 11C-metomidate imaging of adrenocortical cancer. Eur J Nucl Med Mot Imaging 2003;30:403-10.
25. 11C]Metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 2006;91:1410-4.
26. Sohaib SA, Hanson JA, Reznek RH, Trainer PJ, Monson JP, Grossman AB et al. CT appearance of the adrenal glands in adrenocorticotrophic hormone-dependent Cushing Syndrome. AJR 1999;172:997-1002
27. 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumors? Preliminary results in 13 consecutive patients. Eur J Endocrinol 2004; 150:789-92.
28. Fassnacht M, Kenn W, Allolio B. Adrenal tumors: how to establish malignancy? J Endocrinol Invest 2004;27:387-99.
29. Rao SK, Caride VJ, Ponn R, Giakovis E, Lee SH. F-18 fluorodeoxyglucose positron emission tomography-positive benign adrenal cortical adenoma: imaging features and pathologic correlation. Clin Nucl Med 2004;29:300-2.
30. 18F] 2-fluoro-2-deoxy-D- glucose (FDG) uptake of adrenocortical adenoma showing sub clinical Cushing's syndrome. Ann Nucl Med 2003;17:403-6.
31. 18F-FDG uptake in bilateral adrenal hyperplasia causing Cushing's syndrome. Eur J Nucl Med Mot Imaging 2005; 32:384.
32. Leboulleux S, Dromain C, Bonniaud G, Auperin A, Caillou B, Lumbroso J et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 2006;91:920-5.
33. 18F] Fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2oo6;91:2665-71.
34. Kloos RT, Gross MD, Francis IR. Incidentally discovered adrenal masses. Endocr Rev 1995;16:460-84.
35. Frilling A, Tecklenborg K, Weber F, Küller H, Müller S, Stamatis G et al. Importance of adrenal incidentaloma. in patients with a history of malignancy. Surgery 2004;136:1289-96.
36. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 1998;171:201-4.
37. Szolar DH, Korobkin M, Reittner P, Berghold A, Bauernhofer T, Trummer H et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005;234:479-85.
38. Al-Hawary MM, Francis IR, Korobkin M. Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. Best Pract Res Clin Endocrinol Metab 2005;19:277-92.
39. Sahdev A, Reznek RH. Imaging evaluation of the non-functioning indeterminate adrenal mass. Trends Endocrinol Metab 2004;15: 271-6.
40. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Londy F. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AjR Am J Roentgenol 1998; 170:747-52.
41. Outwater EK, Siegelman ES, Radecki PD, Piccoli CW, Mitchell DG. Distinction between benign and malignant adrenal masses: value of Tl-weighted chemical-shift MR imaging. AjR Am J Roentgenol 199505:579-83.
42. Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J Nucl Med 2001;42:884-92.
43. Maurea S, Caraco C, Klain M, Mainolfi C, Salvatore M. Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques. Q J Nucl Med Mot Imaging 2004;48:188-97.
44. Blake MA, Slattery JM, Kalra MK, Halpern EF, Fischman Aj, Mueller PR et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy: initial experience. Radiology 2006;238:970-7.
45. Gross MD, Shapiro B, Shreve P. Radionuclide imaging of the adrenal cortex. Q J Nucl Med 1999;43:224-32.
46. Francis R Korobkin M. Pheochromocytoma. Radiol Clin North Am 1996;34:1101-2.
47. Ilias I, Pacak K. Diagnosis and management of tumors of the adrenal medulla. Horm Metab Res 2005;37:717-21.
48. Shulkin BL, Wieland DM, Baro, ME, Ungar DR, Mitchell DS, Dole MG et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 1996;37:16-21.
49. Shapiro B, Sisson JC, Kalff V, Glowniak J, Satterlee W, Glazer G et al. The location of middle mediastinal pheochromocytomas. J Thorac Cardiovasc Surg 1984;87:814.
50. Rubello D, Bui C, Casara D, Gross MD, Fig LM, Shapiro B. Functional scintigraphy of the adrenal gland. Eur J Endocrinol 2002;147:13-28.
51. Shapiro B, Gross MD, Shulkin BL. Radiosiotope diagnosis and therapy of malignant pheochromocytomas. Trends Endocrinol Metab 2001;12:469-75.
52. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas; imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 1999;212:35-41.
53. Ilias I, Shulkin B, Pacak K. New functional imaging modalities for chromaffin tumors, neuroblastoma. and ganglioneuromas. Trends Endocrinol Metab 2005;16:66-72.
54. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 1992;33: 1125-31.
55. 11C hydroxyephedrine PET. Radiology 2004;230:423-8.
56. 18F]Fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol 2006;13:187-97.
57. 131I]-metaiodobenzylguanidine scintography in the localization of metastatic pheochromocytoma. J Clin Endocrinot Metab 2003;88:4083-7.